Analysts at Zacks Investment Research see sunnier days ahead for the medical device sector during the second half of 2011, despite lingering economic softness and ongoing pressure on the orthopedic market.
Estimating worldwide sales of roughly $300 billion this year, the researchers peg the U.S. market’s share at about $95 billion in 2010.
Sign up to get our free newsletter delivered straight to your inbox
Although 2011 looks brighter than last year, thanks to factors including new product cycles, geographic expansion and the uptake of minimally invasive devices, the impact of 2010’s economic woes and the uncertain health care environment will linger for the rest of the year.
The Japanese earthquake led to global disruptions in supply chains, causing delays in shipments, elective surgical procedures and regulatory clearance for new products. Those could still hit several med-tech makers with significant market exposure in the Land of the Rising Sun.
The Japan Federation of Medical Device Assns. had to fight for priority access to electricity during the rolling blackouts following the disaster to ensure adequate supplies of life-saving and sustaining devices. By June, the FDA was warning of potentially contaminated or water-damaged devices and product shortages for Japanese-made products and components.
Medtronic Inc. (NYSE:MDT), Boston Scientific Corp. (NYSE:BSX) and Johnson & Johnson’s (NYSE:JNJ) DePuy Orthopaedics "have been concerned over the long-term effect of the Japan crisis, which is hard to gauge at this moment,” the analysts wrote.
The researchers also forecast continued headwinds for the orthopedics sector and warned against putting further faith – or dollars – into that market.
"We continue to advise investors to spurn companies in the orthopedic domain," the analysts wrote. "Companies in this space continue to struggle as patients defer their elective procedures given the lingering economic softness, exacerbated by sustained pricing pressure."
Add to that controversies over metal-on-metal hip implants for JNJ/Depuy and Wright Medical Group (NSDQ:WMGI) and bone-growth proteins for Stryker (NYSE:SYK) and Medtronic. Take DePuy, the focal point of a series of lawsuits (over 350 in August alone) filed after its recall of one of its hip replacement lines and evidence that they shed minute metal particles into patients’ bloodstreams.
For life-sustaining products there’s calmer weather ahead, according to Zacks.
"We see growth potential in companies dealing with cardiovascular devices, neuro and radiation oncology products," the analysts wrote. "Also, the radiation oncology market is benefiting from improving trends and technology advancements, providing a compelling growth opportunity."
Zacks named Medtronic, Boston Scientific, St. Jude Medical Inc. (NYSE:STJ), Edwards Lifesciences Corp. (NYSE:EW), Zoll Medical Corp. (NSDQ:ZOLL), Abiomed Inc. (NSDQ:ABMD
and Varian Medical Systems Inc. (NYSE:VAR) as companies poised to do well, thanks to portfolios of life-sustaining products that are less subject to economic instability.
Also supporting the market is a recovery in hospital spending in the U.S., where worn-out equipment is being replaced by newer models, providing another potential driver for the industry.
Here are Zacks’ med-tech companies to watch for the second half of 2011:
